Clinical Trial Update: Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance [Phase 2]

View source ↗

Summary

Phase 2 study evaluating glucarpidase (CPG2) for management of delayed methotrexate clearance in patients with neoplasms; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• Glucarpidase (glucarpidase)

Snippet

Sponsor: BTG International Inc. | Conditions: Neoplasms | Phase 2 | Status: COMPLETED